Cumberland Pharmaceuticals Inc (CPIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has a cash flow conversion efficiency ratio of 0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($387.02K) by net assets ($21.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cumberland Pharmaceuticals Inc net asset quality index to measure how much of total assets are equity-financed.
Cumberland Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Cumberland Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CPIX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Cumberland Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BitNine Co. Ltd.
KQ:357880
|
-0.088x |
|
KEYEAST.Co.Ltd
KQ:054780
|
-0.060x |
|
Sunshine Metals Ltd
AU:SHN
|
-0.037x |
|
Helio SA
WAR:HEL
|
-0.095x |
|
Amata VN PCL
BK:AMATAV
|
0.029x |
|
Regis Corporation Common Stock
NASDAQ:RGS
|
0.026x |
|
Clime Capital Ltd
AU:CAM
|
-0.045x |
|
Alliance Aviation Services Ltd
AU:AQZ
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Cumberland Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Cumberland Pharmaceuticals Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Cumberland Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.54 Million | $4.93 Million | 0.201x | +840.13% |
| 2024-12-31 | $22.55 Million | $-612.19K | -0.027x | -113.04% |
| 2023-12-31 | $29.26 Million | $6.09 Million | 0.208x | -11.37% |
| 2022-12-31 | $35.97 Million | $8.45 Million | 0.235x | +57.84% |
| 2021-12-31 | $42.60 Million | $6.34 Million | 0.149x | +28.87% |
| 2020-12-31 | $46.87 Million | $5.42 Million | 0.116x | +93.09% |
| 2019-12-31 | $51.09 Million | $3.06 Million | 0.060x | +6.81% |
| 2018-12-31 | $55.57 Million | $3.11 Million | 0.056x | +742.00% |
| 2017-12-31 | $63.92 Million | $-557.71K | -0.009x | -212.03% |
| 2016-12-31 | $73.12 Million | $569.48K | 0.008x | -89.82% |
| 2015-12-31 | $76.82 Million | $5.88 Million | 0.077x | -7.70% |
| 2014-12-31 | $80.75 Million | $6.69 Million | 0.083x | +780.86% |
| 2013-12-31 | $79.29 Million | $746.13K | 0.009x | -88.72% |
| 2012-12-31 | $85.57 Million | $7.14 Million | 0.083x | -20.81% |
| 2011-12-31 | $82.84 Million | $8.72 Million | 0.105x | +2260.53% |
| 2010-12-31 | $77.72 Million | $346.66K | 0.004x | -20.45% |
| 2009-12-31 | $72.22 Million | $404.97K | 0.006x | -98.46% |
| 2008-12-31 | $17.55 Million | $6.40 Million | 0.364x | -29.26% |
| 2007-12-31 | $16.75 Million | $8.63 Million | 0.515x | +164.95% |
| 2006-12-31 | $11.13 Million | $2.16 Million | 0.194x | -49.83% |
| 2005-12-31 | $6.23 Million | $2.42 Million | 0.388x | -- |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more